Belinostat Therapy for Peripheral T-Cell Lymphoma

Main Article Content

Rohit Kale Pralhadrao

Abstract

Peripheral T-cell lymphoma (PTCL) is a type of aggressive heterogeneous non Hodgkin type of lymphoma with poor historical outcomes. The responses to conventional chemotherapy remain poor, and many rebound types of cancer growth are seen after initial therapy. The belinostat drug works by inhibiting histone deacetylase and is approved for refractory or relapsed PTCL. The metabolism of Belinostat drug is done by Cytochrome p450, which takes place in the liver. Besides this, no fixed dose combination of belinostat is available for its use as inducer or enzyme inhibitor. Belinostat is well tolerated with mild side effects, including vomiting, nausea, pyrexia, fatigue, and anemic condition in patients undergoing therapy for PTCL. Belinostat therapy is an effective and safe option to treat PTCL. This article mainly deals with pharmacology, drug therapy, efficacy, and applications of belinostat against relapsed or refractory (PTCL).

Downloads

Download data is not yet available.

Article Details

How to Cite
Pralhadrao, R. K. (2022). Belinostat Therapy for Peripheral T-Cell Lymphoma. International Journal of Health Technology and Innovation, 1(02), 19–21. Retrieved from https://ijht.org.in/index.php/ijhti/article/view/38
Section
Review Articles